Microbia, Forest report Phase IIb linaclotide data

Microbia (Cambridge, Mass.) and Forest (NYSE:FRX) reported preliminary data from a pair of double-blind, placebo-controlled Phase IIb trials of linaclotide to treat chronic constipation and constipati...